Grifols, S.A. GRF.MC
Composite 50/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 33/100 — a moderate mark against it.
Valuation ranks 73/100 — a moderate point in its favour. Growth ranks 65/100 — a moderate point in its favour.
Balance-sheet strength ranks 33/100 — a moderate mark against it. Momentum ranks 37/100 — a moderate mark against it. Income ranks 42/100 — a slight mark against it.
What the company does Grifols, S.A. researches, develops, produces, and markets plasma-derived medicines globally across four segments: Biopharma, Diagnostic, Bio Supplies, and Others. Its portfolio includes hemoderivatives for immunology, infectious diseases, and neurology, as well as diagnostic testing equipment and hospital solutions like intravenous fluids.
Key financials Grifols reports gross margins of 38.4%, operating margins of 16.5%, and net margins of 5.6%. Revenue declined -4.8% year-over-year, while EPS grew 43.5%. ROE is 6.1%, ROA 4.2%, and ROCE 6.0%. Debt/Equity stands at 1.17, with a net debt/EBITDA of 5.28 and interest coverage of 1.76.
Stock health The stock shows mixed momentum: +16.64% over 3 months, -2.83% over 6 months, and -18.20% over 12 months. RSI(14) is 75.10, indicating overbought conditions. The Sideravia score is 45.4, with Valuation at 75.4 but Quality at 42.3 and Growth at 36.6.
Price vs fair value The stock trades at a **discount** of 15.80% to our fair-value estimate and a **discount** of 40.18% to the analyst 12-month target. - Strong Biopharma growth highlighted in Q2 2026 earnings calls (Motley Fool, GuruFocus.com, MarketBeat). - Phase 3 trials initiated, testing undervaluation narrative (Simply Wall St.). - European ADRs traded marginally higher, signaling cautious optimism (MT Newswires).
Looking forward Forward P/E is 12.95 (PEG 0.49), and EV/EBITDA is 9.23, suggesting valuation appeal despite weak quality metrics. Phase 3 trials and strategic updates may drive sentiment, but execution risks remain given high leverage and margin pressures.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.